Inozyme Pharma (INZY)
(Delayed Data from NSDQ)
$5.73 USD
-0.05 (-0.87%)
Updated Sep 20, 2024 04:00 PM ET
After-Market: $5.74 +0.01 (0.17%) 7:58 PM ET
3-Hold of 5 3
D Value F Growth F Momentum F VGM
Inozyme Pharma, Inc. (INZY) Price Targets
Average Price Target | Highest Price Target | Lowest Price Target | Upside to Average Price Target |
---|---|---|---|
$19.00 | $40.00 | $13.00 | 228.72% |
Price Target
Based on short-term price targets offered by eight analysts, the average price target for Inozyme Pharma, Inc. comes to $19.00. The forecasts range from a low of $13.00 to a high of $40.00. The average price target represents an increase of 228.72% from the last closing price of $5.78.
Analyst Price Targets (8 )
Broker Rating
Inozyme Pharma, Inc. currently has an average brokerage recommendation (ABR) of 1.11 on a scale of 1 to 5 (Strong Buy to Strong Sell), calculated based on the actual recommendations (Buy, Hold, Sell etc.) made by nine brokerage firms. The current ABR compares to an ABR of 1.13 a month ago based on eight recommendations.
Of the nine recommendations deriving the current ABR, eight are Strong Buy and one is Buy. Strong Buy and Buy respectively account for 88.89% and 11.11% of all recommendations. A month ago, Strong Buy made up 87.5%, while Buy represented 12.5%.
Broker Rating Breakdown
Brokerage Recommendations
Today | 1 Week Ago | 1 Month Ago | 2 Months Ago | 3 Months Ago | |
---|---|---|---|---|---|
Strong Buy | 8 | 8 | 7 | 6 | 6 |
Buy | 1 | 1 | 1 | 1 | 1 |
Hold | 0 | 0 | 0 | 0 | 0 |
Sell | 0 | 0 | 0 | 0 | 0 |
Strong Sell | 0 | 0 | 0 | 0 | 0 |
ABR | 1.11 | 1.11 | 1.13 | 1.14 | 1.14 |
1. Not Ident. Many of the brokerage firms who provide Zacks data ask that we keep their identity confidential.
2. In most cases the # of brokers listed above is less than the # of brokerage firms that have a recommendation on the stock. That is because some firms prohibit Zacks from displaying detailed information on their recommendations such as in the upgrade/downgrade table.
Analyst Upgrades/Downgrades
Date | Brokerage Firm | Analyst | Previous | Current |
---|---|---|---|---|
9/12/2024 | Not Identified | Not Identified | Strong Buy | Strong Buy |
8/13/2024 | Not Identified | Not Identified | Not Available | Strong Buy |
7/2/2024 | Wedbush Securities | David M Nierengarten | Strong Buy | Strong Buy |
7/2/2024 | H.C. Wainwright & Co. | Edward White | Strong Buy | Strong Buy |
5/30/2024 | Wells Fargo Securities | Tiago Fauth | Not Available | Strong Buy |
5/8/2024 | Needham & Company | Joseph R Stringer | Moderate Buy | Moderate Buy |
4/1/2024 | Cowen & Co. | Marc Frahm | Strong Buy | Strong Buy |
1. Not Ident. Many of the brokerage firms who provide Zacks data ask that we keep their identity confidential.
2. In most cases the # of brokers listed above is less than the # of brokerage firms that have a recommendation on the stock. That is because some firms prohibit Zacks from displaying detailed information on their recommendations such as in the upgrade/downgrade table.
Average Brokerage Rating
Current ABR | 1.11 |
ABR (Last week) | 1.11 |
# of Recs in ABR | 9 |
Average Target Price | $19.00 |
LT Growth Rate | NA |
Industry | Medical - Biomedical and Genetics |
Industry Rank by ABR | 79 of 253 |
Current Quarter EPS Est: | -0.44 |
INZY FAQs
Inozyme Pharma, Inc. (INZY) currently has an average brokerage recommendation (ABR) of 1.11 on a scale of 1 to 5 (Strong Buy to Strong Sell), calculated based on the actual recommendations (Buy, Hold, Sell etc.) made by 9 brokerage firms.
The average price target for Inozyme Pharma, Inc. (INZY) is $19.00. The current on short-term price targets is based on 7 reports.
The forecasts for Inozyme Pharma, Inc. (INZY) range from a low of $13 to a high of $40. The average price target represents a increase of $231.59 from the last closing price of $5.73.
The current UPSIDE for Inozyme Pharma, Inc. (INZY) is 231.59%
Based on short-term price targets offered by eight analysts, the average price target for Inozyme Pharma, Inc. comes to $19.00. The forecasts range from a low of $13.00 to a high of $40.00. The average price target represents an increase of 228.72% from the last closing price of $5.78.